NitroMed
Emerging pharmaceutical company with substantial expertise and intellectual property in nitric oxide-based drug development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Series A | |
| N/A | N/A | Series B | |
| N/A | N/A | Series C | |
| N/A | N/A | Series D | |
$31.4m | Series E | ||
| N/A | N/A | IPO | |
N/A | Acquisition | ||
| Total Funding | €28.5m | ||